COVID-19 Clinical Trial
Official title:
A Multicenter, Double-blind, Randomized, Placebo-controlled, Loaded Phase III Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19
Verified date | February 2024 |
Source | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multicenter, double-blind, randomized, placebo-controlled, loaded Phase III clinical study. This test is in a new coronavirus infection pneumonia diagnosis and treatment plan of 9 (trial version) "(SoC), on the basis of the standard treatments according to the results of clinical studies have been obtained, using a dose of 0.2 mg/kg, and a placebo. The regimen consisted of a single intravenous infusion of Meplazumab or placebo on day 1 (d0) of the treatment period and d7 after initial administration at a dose of 0.2 mg/kg calculated according to body weight. It is expected that 350 subjects will be randomly assigned to Meplazumab or placebo in a 1:1 ratio. Short-term efficacy evaluation was performed for each subject within 28 days after initial administration to determine the therapeutic efficacy and safety of Meplazumab. Long-term follow-up evaluation was performed within 56 days of initial administration to determine the safety of Meplazumab in each subject.
Status | Suspended |
Enrollment | 108 |
Est. completion date | May 30, 2024 |
Est. primary completion date | April 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 84 Years |
Eligibility | Inclusion Criteria: 1. Age 18 to 80 (including 18 and 80 years old), male and female, 2. By PCR detection method for nucleic acid amplification, laboratory confirmed SARS - CoV - 2 adults infected (within 72 hours before delivery) for the first time; 3. Comply with national WeiJianWei "new coronavirus infection pneumonia diagnosis and treatment plan 9 (trial version)" clinical confirmed new coronavirus pneumonia patients (heavy); 4. Agree to sign a consent form to test within 6 months after the effective non-pharmaceutical precautions; 5. Participants must be able to understand and willing to participate in this research, this study and signed informed consent form (if incapacitated subjects, the researchers believe the subjects to the test in its own interests, should be signed by its legal guardian informed consent, or telephone inform consent (recording) and note it in the original medical records and other relevant documents). Exclusion Criteria: 1. In the investigator's judgment, the subject has any physical examination results, laboratory abnormalities, and/or any history of disease that would endanger his safety by participating in the study; 2. Comply with national WeiJianWei "new coronavirus infection pneumonia diagnosis and treatment plan 9 (trial version)" clinical diagnosis of type new coronavirus pneumonia in critically ill patients; 3. Line 4 severe chronic kidney disease, or need dialysis (that is, the estimated glomerular filtration rate (eGFR) < 30 mL/min / 1.73 m2), or within 7 days of the serum creatinine increased 44.2 mu mol/L, or oliguria (< 400 mL / 24 hours) or no urine (< 100 mL / 24 hours); 4. During pregnancy or lactation; 5. Will be moved to within 72 hours is not the another hospital research center; 6. Research on any drug allergies; 7. Used as anticancer drugs, graft rejection drugs or immune regulating biological agents (group into the first 30 days or five half-life [will be subject to a long time]); 8. Long-term use of corticosteroids and oral > 10 mg prednisone, a day for 3 months or more (allow oral every other day 10 mg prednisone); 9. Randomization or research within 2 weeks before treatment and safety shall not be used during the follow-up period live vaccine (live attenuated); 10. At the same time to participate in another clinical research subjects. A washout period of 5 half-lives (depending on the drug under study or 30 days from any previous study, whichever is longer) is required; 11. Total bilirubin (TBL) > 2 x normal limit (ULN), and alanine aminotransferase (ALT) > 5 x ULN, or aspartate amino transferase (AST) > 5 x ULN, or alkaline phosphatase (> 5 x ULN; 12. Platelet < 50 * 109 / L, or hemoglobin < 70 g/L; 13. Researchers say other factors not appropriate in this test. Note: researchers should ensure that participants when screening meets all inclusion/exclusion standard. If a subject's status changes (including laboratory results) between screening and initial dosing and if the subject meets one of the exclusion criteria, the subject shall be excluded from the study. |
Country | Name | City | State |
---|---|---|---|
China | First Affiliated Hospital of the Air Force Medical University | Xi'an |
Lead Sponsor | Collaborator |
---|---|
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mortality | All-cause mortality at day 28 (d28) | Day 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Active, not recruiting |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|